4688美高梅

中国4688美高梅集团(股份)有限公司-官方网站

News Center

Pharma Sources Exclusive: Doer Biologics COO Dr. Fang Yongliang Unveils the Therapeutic Potential and Clinical Development of Triple Agonist DR10624

2026/07/23

Read more

Doer Biologics' Global First-in-Class Triple Agonist DR10624 Receives China IND Approval for HFpEF/HFrEF

2026/07/14

Read more

EASL China Voice: DR10624 Phase II Results Show Significant Liver Fat Reduction and Metabolic Improvements in Severe Hypertriglyceridemia

2026/06/03

Read more

EASL 2026 | Doer Biologics Presents Results from a Phase 2 Study of DR10624 in Severe Hypertriglyceridemia on Liver Fat and Improvement of Hepatic Metabolic Markers

2026/05/28

Read more

AACR 2026｜Doer Bio Presents DR319-DP, a Bispecific Bipayload ADC, Demonstrating Breakthrough Potential in Overcoming Efficacy and Resistance Challenges in Solid Tumors

2026/05/25

Read more

Doer Biologics Honored as Hangzhou Quasi-Unicorn for Sixth Consecutive Year

2026/04/24

Read more

AACR 2026 | Doer Biologics Presents Preclinical Data on Bispecific Dual-Payload ADC

2026/04/16

Read more

Doer Biologics to Present Preclinical Results of DR319 Project at AACR 2026

2026/03/24

Read more

Approval of IND Application in China for Doer's DR30206 Injection Combined with Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

2026/03/03

Read more

Dr. Yongliang Fang on Endpoints News：Chinese biotech unveils first-in-class tri-agonist for high lipids

2025/12/31

Read more
【网站地图】